<DOC>
	<DOCNO>NCT00362414</DOCNO>
	<brief_summary>The purpose study assess safety Beta-hCG + Erythropoietin patient acute ischemic stroke .</brief_summary>
	<brief_title>Beta-hCG + Erythropoietin Acute Stroke</brief_title>
	<detailed_description>Patients new stroke evaluate University California Irvine Medical Center ( UCIMC ) , JCAHO-certified Stroke Center , Hoag Memorial Hospital Presbyterian . Standard stroke pathway use identify patient initiate standard care therapy . Patients potentially eligible study enrollment identify , screen , consent enrolled . Those meeting entry criterion , exclusion criterion , undergo additional baseline test include brain MRI . A 9-day course B-E therapy begin , always within 48 hour stroke onset . This therapy consist hCG ( 3 once-daily IM dose 10,000 IU per dose , one day apart , day 1 , 3 5 study participation ) , follow one day washout period ( day 6 ) , follow Epo ( three once-daily i.v . dose 30,000 IU per dose day 7 , 8 , 9 study participation ) . Patients examine several time point therapy , well 6 week 3 month stroke onset . The primary outcome measure relate safety , secondary outcome measure related disability , neurological status , MRI measure .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>1 . Age 2185 2 . NIHSS score 624 time enrollment , ensure stroke neither mild devastate 3 . Stroke ischemic origin , supratentorial , radiologically confirm 4 . Patient 2448 hour time stroke onset time first dose BE therapy administer . Time onset symptoms begin , stroke occurred sleep , time onset patient last see normal . 5 . Reasonable expectation availability receive full 9 day BE therapy course 6 . Reasonable expectation patient receive standard poststroke physical , occupational , speech , cognitive therapy indicate 1 . Preexisting active major psychiatric neurological disease 2 . History significant alcohol drug abuse prior 3 year 3 . Serum hemoglobin &gt; 16 g/dL male patient &gt; 14 g/dL female patient ; platelet count &gt; 400,000/mm3 either male female patient 4 . Advanced liver , kidney , cardiac , pulmonary disease ; former operationally define serum bilirubin &gt; 4 mg/dL , alkaline phosphatase &gt; 250 U/L , SGOT &gt; 150 U/L , SGPT &gt; 150 U/L , creatinine &gt; 3.5 mg/dL 5 . Pregnancy lactate ; note negative pregnancy test require patient female reproductive year , use test reliably detect betahCG level &gt; 25 normal level &lt; 8 IU/L . 6 . Contraindication study participation basis follow : 1 . Allergy contraindication initiate either betahCG Erythropoietin 2 . Known hypersensitivity mammalian cellderived product hypersensitivity albumin 3 . A known diagnosis prostatic cancer ; note prostate specific antigen collect retrospective assessment safety , use ascertain study eligibility 4 . Dysuria unexplained origin 5 . Uncontrolled hypertension , define context acute stroke blood pressure persistently 220 mm Hg systolic 120 diastolic despite antihypertensive therapy 7 . Current use either betahCG Erythropoietin 8 . Other condition know elevate betahCG , active prior 24 month , e.g. , choriocarcinoma germ cell tumor 9 . Terminal medical diagnosis consistent survival &lt; 1 year 10 . Known hypercoagulable state , purpose study deficiency protein C , S , antithrombin III ; activate protein C resistance ; prothrombin gene mutation ; antiphospholipid antibody syndrome base clinical laboratory measure .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Stroke</keyword>
</DOC>